Cargando…

1193. Impact of Removing Extended-spectrum Beta Lactamase Status Labeling from Culture Reports on Carbapenem Use for Non-bacteremic Patients With Urinary Tract Infections: A Multi-hospital Assessment

BACKGROUND: Reporting extended-spectrum beta lactamase (ESBL) status on microbiology results for Enterobacterales is not required by laboratory, infection prevention, or antimicrobial stewardship guidelines. Ceftriaxone (CRO) resistance may be utilized as a proxy for ESBL production. Current practic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarado, Lourdes R Menendez, Landayan, Alice Margulis, Williams, Kelsey N, Frederick, Corey M, Murillo, Jorge, Gauthier, Timothy P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677359/ http://dx.doi.org/10.1093/ofid/ofad500.1033

Ejemplares similares

Clinical Outcome of Bacteremic Spontaneous Bacterial Peritonitis due to Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella Pneumoniae
por: Kang, Cheol-In, et al.
Publicado: (2004)

Extended-Spectrum Beta-Lactamase and Carbapenem-Resistant Gram-Negative Pathogens in Makkah, Saudi Arabia
por: Kabrah, Ahmed
Publicado: (2022)

Virulence Profiles of Bacteremic Extended-Spectrum β-Lactamase-Producing Escherichia coli: Association with Epidemiological and Clinical Features
por: Rodríguez-Baño, Jesús, et al.
Publicado: (2012)

Extended spectrum beta-lactamase urinary tract infections
por: Aboumarzouk, Omar M.
Publicado: (2014)

Genome Sequence of Colistin-Resistant Bacteremic Shewanella algae Carrying the Beta-Lactamase Gene bla (OXA-55)
por: Chen, Ying-Ju, et al.
Publicado: (2019)

1193. Comparison of the Clinical Outcomes of Patients With IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenem-Sensitive Enterobacteriaceae in Japan
por: Saito, Sho, et al.
Publicado: (2018)

Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens
por: Banerjee, Sayantan, et al.
Publicado: (2017)

Extended-Spectrum Beta-Lactamase-Producing and Carbapenem-Resistant Enterobacterales in Companion and Animal-Assisted Interventions Dogs
por: Roscetto, Emanuela, et al.
Publicado: (2021)

Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae
por: Katip, Wasan, et al.
Publicado: (2021)

Epidemiology of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales in US children, 2016–2020
por: Grome, Heather, et al.
Publicado: (2023)

Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana
por: Sampah, James, et al.
Publicado: (2023)

211. Disease burden of bacteremia with extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae in Korea
por: Mi Lee, Chan, et al.
Publicado: (2023)

Case Report: Fatal Outcome for a Preterm Newborn With Meningitis Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 1193
por: Oldendorff, Frida, et al.
Publicado: (2022)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

Oral beta-lactam step down in bacteremic E. coli urinary tract infections
por: Saad, Stephan, et al.
Publicado: (2020)

Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa
por: Farajzadeh Sheikh, Ahmad, et al.
Publicado: (2014)

Predicting Extended-Spectrum Beta-Lactamase and Carbapenem Resistance in Enterobacteriaceae Bacteremia: A Diagnostic Model Systematic Review and Meta-Analysis
por: Timbrook, Tristan T., et al.
Publicado: (2023)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019)

Reporting Extended-Spectrum β-Lactamase Positivity May Reduce Carbapenem Overuse
por: Tamma, Pranita D, et al.
Publicado: (2019)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
por: Bhowmick, Tanaya, et al.
Publicado: (2020)

1689. Oral Beta-lactam Step Down in Bacteremic E. coli Urinary Tract Infections
por: Saad, Stephan, et al.
Publicado: (2020)

Phenotypic and genotypic detection of metallo-beta-lactamases in Carbapenem resistant Acinetobacter baumannii
por: Moulana, Zahra, et al.
Publicado: (2020)

343 Risk Factors for Extended-Spectrum Beta-Lactamase Infection and Evaluation of Carbapenem Use Patterns and Appropriateness in a County Hospital Setting
por: Su, Henry, et al.
Publicado: (2014)

Colonisation with extended spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales in children admitted to a paediatric referral hospital in South Africa
por: Ogunbosi, Babatunde O., et al.
Publicado: (2020)

Extended spectrum beta lactamase peritonitis: Time for innovation?
por: Sinha, R., et al.
Publicado: (2012)

Extended spectrum beta lactamase peritonitis: Our experience
por: Cavoli, G. L., et al.
Publicado: (2013)

716 Risk Factors for Resistance to Beta-lactam/Beta-lactamase Inhibitors and Carbapenems in Bacteroides spp. Bacteremia
por: Smith, Janessa, et al.
Publicado: (2014)

Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections
por: Vachvanichsanong, P., et al.
Publicado: (2020)

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
por: Hefler, Jade L, et al.
Publicado: (2019)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Critically Ill Patients: Impact of Carriage And Infection On Carbapenem Consumption, Duration of Icu Stay, And Mortality
por: Barbier, F, et al.
Publicado: (2015)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

1193. Human Transcriptomic Analysis of Periprosthetic Joint Infection
por: Masters, Thao, et al.
Publicado: (2020)

Detection of extended spectrum beta lactamases, ampc beta lactamases and metallobetalactamases in clinical isolates of ceftazidime resistant Pseudomonas Aeruginosa
por: Umadevi, Sivaraman, et al.
Publicado: (2011)

Exposure assessment of extended-spectrum beta-lactamases/AmpC beta-lactamases-producing Escherichia coli in meat in Denmark
por: Carmo, Luís P., et al.
Publicado: (2014)

The Novel CarbaLux Test for Carbapenemases and Carbapenem Deactivating AmpC Beta-Lactamases
por: Pfaendler, Hans Rudolf, et al.
Publicado: (2020)

Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms
por: Mody, Rupal M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ss6pfc1ch6181iiejt2ndbv81t